Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Special and immunohistochemical stains are not routinely needed for diagnosing hair disorders.

A gene deletion in mice causes weak protein, immune issues, hair loss, airway problems, and wasting disease.

People with vitiligo may have a higher rate of Helicobacter pylori infection, but the infection's severity doesn't affect how severe the vitiligo is.

Genetic mutation and carcinogen treatment are both needed for skin cancer to develop in these specific mice.

Genetic factors affect hair loss, and molecular testing may help predict, diagnose, and treat it.

Some treatments can help hair regrowth in alopecia areata, but none offer a cure, and effectiveness varies.

The conditions alopecia areata, primary sclerosing cholangitis, and ulcerative colitis may be linked by shared autoimmune and cell death mechanisms.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Short telomeres contribute to aging and cancer, and while telomerase can delay aging, it may also promote cancer.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Lipid–polymer hybrid nanoparticles can improve genome editing delivery and outcomes.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Solanum nigrum shows promise for treating COVID-19 and its complications, but more research is needed.

Frontal fibrosing alopecia may be linked to genital Lichen sclerosus through an autoimmune process.

Calcipotriol works almost as well as clobetasol for mild to moderate alopecia areata with fewer side effects.

Some plant-based chemicals may help with hair growth, but more research is needed to confirm their effectiveness.

Treating alopecia areata every 3 weeks with diphenylcyclopropenone is more effective than weekly treatments.

Transfollicular drug delivery is promising but needs more research to improve and understand it better.

Malondialdehyde-modified DNA may trigger an immune response in alopecia areata patients.

A new skin disease in four Labrador retrievers responded well to immunosuppressive treatment.

Vitamin D levels are not linked to alopecia areata.

Human placenta hydrolysates help treat various diseases and aid healing.

Different types of fibroblasts play various roles in kidney repair and aging, and may affect chronic kidney disease outcomes.

COVID-19 may affect male fertility and women might have better outcomes due to hormonal and immune differences.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

Both topical calcipotriol and narrowband UVB improved alopecia, but combining them didn't enhance the effect on hair loss severity, despite higher vitamin D3 levels.

Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.

People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.